5 Revealing Analyst Questions From Avantor's Q2 Earnings Call

Avantor’s second quarter results were met with a sharply negative market reaction, as investors focused on ongoing margin contraction and heightened competitive intensity. Management attributed the quarter’s performance to a combination of pricing actions in the Laboratory Solutions business aimed at protecting and growing market share, as well as discrete operational headwinds in Bioscience Production, including extended maintenance at a manufacturing facility and unexpected challenges at several large bioprocessing customers. CEO Michael Stubblefield acknowledged that, despite sequential improvement in organic revenue, “competitive intensity remains high across our industry,” and noted that these dynamics, along with unfavorable product mix and higher supply chain expenses, weighed on profitability.

Is now the time to buy AVTR? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Avantor’s Q2 Earnings Call

• Vijay Muniyappa Kumar (Evercore): Asked whether margin pressures from pricing actions would persist into next year. CFO Brent Jones said the effects would last through the year, with margin recovery depending on volume uptake from contract wins.
• Michael Leonidovich Ryskin (Bank of America): Questioned the sustainability of bioprocessing growth in light of recurring one-off issues. CEO Michael Stubblefield emphasized strong underlying demand in monoclonal antibodies but acknowledged that recent setbacks from customer-specific issues may persist in the short term.
• Daniel Gregory Brennan (TD Cowen): Probed the extent of competitive pricing pressure and volume trends in Laboratory Solutions. Stubblefield admitted to stepped-up competitive intensity, especially among large biopharma accounts, and said volume was relatively stable while price was the main margin headwind.
• Rachel Marie Vatnsdal Olson (JPMorgan): Sought clarity on the rationale for lowering Lab Solutions guidance despite stable trends. Jones said the move reflected a prudent, “realistic outlook” that assumes no material improvement in the environment through year-end.
• Tycho W. Peterson (Jefferies): Inquired about the mechanics of contract-related rebates and the path to margin stabilization. Management confirmed upfront rebates impact free cash flow and margins in the near term but dismissed concerns about channel stuffing, stating volume gains should eventually support margin improvement.

Catalysts in Upcoming Quarters

In the next few quarters, the StockStory team will closely monitor (1) the pace at which new contract wins in Laboratory Solutions translate into higher volumes and improved operating leverage, (2) signs of stabilization or improvement in the bioprocessing segment as customer-specific headwinds are addressed, and (3) the initial impact of Emmanuel Ligner’s leadership on strategic direction. Progress on cost transformation and digital initiatives will also be key signposts for margin recovery.

Avantor currently trades at $12.70, down from $13.45 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.